The compiler infers, but does not take instructions. There is no syntax for explicit type declarations yet, and the new type ...
Some Canadians will be able to buy brand-name GLP-1 drug Ozempic at a reduced price, Danish drugmaker Novo Nordisk said in a statement Tuesday. The move comes as two generic versions of Ozempic and ...
India got it earlier this year, and Canada approved it last month. But when is the United States going to get a generic version of Ozempic? Limited time: Save 25% on NBC News subscription Get ...
A version of this article first appeared in CNBC's Healthy Returns newsletter, which brings the latest health-care news straight to your inbox. Subscribe here to receive future editions. The day has ...
WASHINGTON, April 29 (Reuters) - The U.S. Supreme Court on Wednesday heard a patent dispute over a generic version of Amarin Pharma's (AMRN.O), opens new tab cardiovascular drug Vascepa that could ...
A Supreme Court case heard this week could give brand-name drugmakers longer monopolies, delay generic competition, and leave patients paying higher prices. When it comes to generic medications, ...
The FDA has approved the first generic versions of Farxiga, a drug used to treat Type 2 diabetes and reduce the risk of hospitalization for heart failure. The generic, dapagliflozin, is indicated to ...
India is launching cheap weight-loss drugs — but Novo Nordisk is betting its brands will stay on top
Novo lost semaglutide patent protection in India, triggering generic launches. Indian drugmakers launched generic versions at lower prices. Novo cut prices and used partnerships to defend market share ...
The blockbuster weight loss drug sold as Ozempic and Wegovy will soon go generic in countries that are home to 40% of the world’s population, significantly lowering the price of a costly medicine that ...
The weight-loss world is on the brink of a major shake-up. Pharmaceutical companies in India will get the green light this weekend to start selling generic versions of Ozempic and Wegovy, with several ...
In India, China and several other nations, Novo Nordisk is on the verge of losing patent protection for its blockbuster weight loss drug, opening the door for cheaper competing versions. By Rebecca ...
A revolution is coming in the U.S. generics marketplace, one that has the potential to transform savvy organizations into engines of growth, and to end the decades-long “race to the bottom” that for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results